Why the study?
What is the recommended role of chemotherapy in the management of osteosarcoma of the jaw?
What is the recommended role of chemotherapy in the management of osteosarcoma of the jaw?
There is a lack of consensus regarding the use of chemotherapy in osteosarcoma of the jaw, highlighting the need for a standardized treatment algorithm.
No consensus on chemotherapy for jaw osteosarcoma; leaves open need for prospective trials and standardized guidelines.
Neoadjuvant chemotherapy for osteosarcoma of the jaw (OSJ) remains controversial despite being a standardized treatment in osteosarcoma of the long bones. We present a case of a 22-year-old male with OSJ and performed a retrospective systemic review of previously published literatures of OSJ. We identified 27 articles: 7% recommended neoadjuvant chemotherapy, 22% recommended adjuvant chemotherapy, 19% recommended both neoadjuvant and adjuvant chemotherapy, 33% recommended against chemotherapy and 19% stated the role of chemotherapy is unknown. The lack of consensus regarding the use of chemotherapy in OSJ, despite its benefits, demonstrates the need to establish a standardized algorithm for OSJ.
No takes yet. Share an insight, caveat, or question.
Kuo et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: